3 enrolling by invitation. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 3 |
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Endocrine System Diseases: new trials by email Literature Review of Endocrine System Diseases trials Research Report on Endocrine System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients Trelagliptin 100 mg, Sitagliptin 100mg OD - Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus | Phase 3 | Enrolling by invitation | Khyber Medical College, Peshawar | 126 | 2025-07-01 | 2025-07-18 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 24 | 2025-04-22 | 2026-07-16 |
| A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia TransCon CNP - Achondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | Ascendis Pharma Growth Disorders A/S | 140 | 2023-06-21 | 2026-08-17 |
Dwarfism (2) · Achondroplasia (1) · Bone Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Genetic Diseases, Inborn (1) · Hypochondroplasia (1) · Mucopolysaccharidosis IV (1) · Musculoskeletal Diseases (1) · Osteochondrodysplasias (1)
Bone Diseases, Developmental (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Bone Diseases (1) · Carbohydrate Metabolism, Inborn Errors (1) · Connective Tissue Diseases (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Lysosomal Storage Diseases (1) · Metabolism, Inborn Errors (1) · Mucinoses (1) · Mucopolysaccharidoses (1) · Musculoskeletal Diseases (1)
Sitagliptin Phosphate (1) · infigratinib (1) · trelagliptin (1)
Ascendis Pharma Growth Disorders A/S (1) · Khyber Medical College, Peshawar (1) · QED Therapeutics, a BridgeBio company (1)
Australia (2) · Canada (2) · France (2) · Portugal (2) · Spain (2) · United Kingdom (2) · United States (2) · Austria (1) · Denmark (1) · Germany (1) · Ireland (1) · New Zealand (1) · Norway (1) · Pakistan (1) · Singapore (1)